Literature DB >> 11741177

Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide.

Daniela Basso1, Anna Valerio, Roberta Seraglia, Saverio Mazza, Maria Grazia Piva, Eliana Greco, Paola Fogar, Nicoletta Gallo, Sergio Pedrazzoli, Antonio Tiengo, Mario Plebani.   

Abstract

INTRODUCTION: Pancreatic adenocarcinoma causes diabetes mellitus by releasing factors interfering with glucose metabolism. AIMS: We verified in isolated rat hepatocytes the molecular weight (MW) of the fraction from pancreatic cancer cell conditioned media (CM) that altered glucose metabolism and ascertained, using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis, whether there is any common peptide in CM and in the sera of patients with pancreatic cancer.
METHODOLOGY: Sera was obtained from patients with pancreatic cancer ( n = 14) and chronic pancreatitis ( n = 9) and healthy control subjects ( n = 10). Conditioned medium (CM) was obtained from the following cell lines: MIA PaCa 2, PSK-1, PANC-1, and CAPAN-1. Two fractions (MW of less than 30,000 Da and less than 10,000 Da) were obtained from patients' sera, from CM, and from non-CM (NCM) after two-step ultrafiltration. Rat hepatocytes were incubated with CM and NCM. The peptide profile of patients' sera, CM, and NCM were analyzed using MALDI-MS.
RESULTS: In rat hepatocytes, glucose metabolism was impaired by CM from all the pancreatic cancer cell lines and by CM with an MW of less than 10,000 Da. Two peptides (m/z 2030 and 2726) were found in CM and patients' sera. Only the peptide at m/z 2030 was found to be associated with the presence of diabetes.
CONCLUSION: A peptide at m/z 2030 may be a putative pancreatic cancer-associated diabetogenic factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741177     DOI: 10.1097/00006676-200201000-00002

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  22 in total

1.  Diabetes and pancreatic cancer.

Authors:  Donghui Li
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Synthesis and characterization of hydrogel particles containing Cibacron Blue F3G-A.

Authors:  Alexis Patanarut; Alessandra Luchini; Palma J Botterell; Anirudh Mohan; Caterina Longo; Paul Vorster; Emanuel F Petricoin; Lance A Liotta; Barney Bishop
Journal:  Colloids Surf A Physicochem Eng Asp       Date:  2010-06       Impact factor: 4.539

3.  Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer.

Authors:  Katherine Y Fan; Avani S Dholakia; Aaron T Wild; Zheng Su; Amy Hacker-Prietz; Rachit Kumar; Mary Hodgin; Charles C Hsu; Dung T Le; Ana De Jesus-Acosta; Luis A Diaz; Daniel A Laheru; Ralph H Hruban; Elliot K Fishman; Todd D Brown; Timothy M Pawlik; Christopher L Wolfgang; Phuoc T Tran; Joseph M Herman
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

Review 4.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

Review 5.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

6.  Probability of pancreatic cancer following diabetes: a population-based study.

Authors:  Suresh T Chari; Cynthia L Leibson; Kari G Rabe; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

7.  Diabetes Type 2 and Pancreatic Cancer: A History Unfolding.

Authors:  Andre De Souza; Khawaja Irfan; Faisal Masud; Muhammad Wasif Saif
Journal:  JOP       Date:  2016-03

Review 8.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

9.  Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Cynthia L Leibson; Kari G Rabe; Lawrence J Timmons; Jeanine Ransom; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Am J Gastroenterol       Date:  2009-06-09       Impact factor: 10.864

10.  Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.

Authors:  Gaurav Aggarwal; Vijaya Ramachandran; Naureen Javeed; Thiruvengadam Arumugam; Shamit Dutta; George G Klee; Eric W Klee; Thomas C Smyrk; William Bamlet; Jing Jing Han; Natalia B Rumie Vittar; Mariza de Andrade; Debabrata Mukhopadhyay; Gloria M Petersen; Martin E Fernandez-Zapico; Craig D Logsdon; Suresh T Chari
Journal:  Gastroenterology       Date:  2012-09-06       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.